GlassScriptPhysician profile
Shany Quevedo
NPI 1033798400
$2,110.47
in general payments reported to CMS, 2019-2025
16 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $143 · 2023: $332 · 2024: $516 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872 · Education: $95.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.04 |
| Education | $95.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $519.84 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $457.45 | 2024-2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $242.75 | 2023 | |
| Novo Nordisk INC | $161.90 | 2022-2025 | Wegovy |
| Boston Scientific Corporation | $143.07 | 2024 | Watchman Flx |
| Abbvie INC. | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.60 | 2024 | Zeposia |
| Mirum Pharmaceuticals, INC. | $100.26 | 2025 | Livmarli |
| Pfizer INC. | $89.22 | 2023 | |
| Pharmacosmos Therapeutics INC. | $33.75 | 2024 | Monoferric |
| Ardelyx, INC. | $23.24 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $22.76 | 2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $20.00 | 2024 | |
| Dexcom, INC. | $19.37 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.78 | 2024 | Xifaxan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shany Quevedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.